Cognition Therapeutics Inc. (NASDAQ: CGTX)
$0.6161
-0.0140 ( -2.21% ) 2.6M
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Market Data
Open
$0.6161
Previous close
$0.6301
Volume
2.6M
Market cap
$25.56M
Day range
$0.5780 - $0.6370
52 week range
$0.3400 - $2.9500
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jun 11, 2024 |
4 | Insider transactions | 1 | Jun 11, 2024 |
4 | Insider transactions | 1 | Jun 11, 2024 |
4 | Insider transactions | 1 | Jun 11, 2024 |
4 | Insider transactions | 2 | Jun 11, 2024 |
8-k | 8K-related | 13 | Jun 07, 2024 |
10-q | Quarterly Reports | 59 | May 07, 2024 |
8-k | 8K-related | 15 | May 07, 2024 |
4 | Insider transactions | 1 | May 03, 2024 |
ars | Annual reports | 1 | Apr 26, 2024 |